Treating endometriosis pain: stepped medical approach and integrative options
Key Takeaways
Medical treatment of endometriosis pain follows a stepped approach: NSAIDs and continuous combined hormonal contraceptives in first line, dienogest in second line, GnRH agonists with mandatory add-back in third line for refractory cases, and aromatase inhibitors in selected situations. Pelvic floor physiotherapy and cognitive behavioural therapy complement the medical strategy. In adolescents, early hormonal treatment is first line per ESHRE 2022. Doses are individualised by your doctor.
Why a stepped approach
Endometriosis pain is complex: an inflammatory component (painful cycles), a mechanical component (adhesions, deep lesions), a neuropathic component (central sensitisation after years of chronic pain), and a myofascial component (a hypertonic pelvic floor). No single drug covers all of these dimensions.
The stepped approach proposed by ESHRE 2022 (Becker et al., Human Reproduction Open) individualises treatment according to:
- pain intensity;
- pregnancy plans (suppressive treatments prevent pregnancy);
- individual tolerance and acceptable side-effect profile;
- co-morbidities (migraine, prior thromboembolic events, bone profile, mood disorders).
Your doctor determines the strategy and dose suited to your situation. This article describes the available options; it does not replace a consultation. For the overview (diagnosis, infertility, surgery), see the complete endometriosis guide.
First line: NSAIDs and combined hormonal contraceptives
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are used on demand during painful episodes. They inhibit cyclo-oxygenase, the activity of which is increased in endometriotic tissue. Their efficacy is variable and prolonged high-dose use carries digestive, renal and cardiovascular risks — they are not a chronic stand-alone solution.
Combined hormonal contraceptives (CHC)
ESHRE 2022 issues a strong recommendation in favour of combined hormonal contraceptives as first-line treatment for endometriosis pain. Several routes are possible:
- Combined oral pill;
- Vaginal ring;
- Transdermal patch.
The most effective regimen against pain is continuous or extended-cycle use (no monthly break), which suppresses menstruation. This approach has shown significant reductions in dysmenorrhoea, chronic pelvic pain and deep dyspareunia.
The usual CHC contraindications apply: prior thromboembolic event, migraine with aura, uncontrolled hypertension, smoking after age 35, etc.
Second line: progestins
Dienogest 2 mg/day
Dienogest is a progestin specifically developed for endometriosis. Randomised trials (Strowitzki et al., 2010, Hum Reprod) showed efficacy comparable to leuprolide acetate for pain, with a better bone-tolerance profile over 24 months and an acceptable bleeding pattern (irregular bleeding at the start of treatment, then amenorrhoea in many patients).
Common side effects include intermenstrual bleeding, modest weight gain and occasionally mood changes.
Other progestin options
- Levonorgestrel-releasing IUS (LNG-IUS): useful when local contraception is desired, especially with associated adenomyosis, or in adolescents after oral failure.
- Etonogestrel implant: durable progestin-only option without oestrogens.
- Medroxyprogesterone acetate, norethisterone: classical options usable depending on context.
The choice between these routes is guided by bleeding profile, contraceptive needs, tolerance and adherence.
Third line: GnRH agonists with add-back
GnRH agonists (leuprolide, triptorelin, goserelin, nafarelin) suppress the hypothalamic-pituitary-ovarian axis and create an artificial menopause, depriving endometriotic tissue of oestrogens.
These are powerful agents but they expose patients to significant side effects: hot flushes, sleep disturbance, vaginal dryness, bone loss of about 6 % per year without protective therapy.
Several principles frame their use:
- reserved for refractory cases after the previous steps;
- mandatory add-back therapy from day one, with norethisterone or low-dose oestrogen plus progestin, to limit hot flushes and bone loss;
- duration limited to 6 to 12 months;
- bone densitometry considered in case of prolonged use or associated risk factors.
Add-back does not reduce the analgesic efficacy of GnRH agonists and is now considered standard prescribing.
Aromatase inhibitors: a niche option
Aromatase inhibitors (letrozole, anastrozole) block local conversion of androgens to oestrogens in endometriotic tissue, which aberrantly expresses aromatase.
- In postmenopausal women with painful residual endometriosis, they can be used alone.
- In women of reproductive age, they must always be paired with a progestin or combined contraceptive to prevent functional cyst formation and block ovulation.
This indication remains off-label in several countries. It is reserved for refractory cases in specialised settings, after clear discussion with the patient.
Integrative approaches
Pelvic floor physiotherapy
Recommended by ESHRE 2022 when a myofascial component is present (hypertonic pelvic floor, levator contracture, musculoskeletal dyspareunia). A pelvic-health physiotherapist assesses tone and coordination and teaches release techniques. This dimension is often under-treated.
Cognitive behavioural therapy (CBT)
Useful for the chronic-pain component with central sensitisation, anxiety or depressive impact, and quality-of-life burden. It does not “remove” the pain but teaches strategies to manage it.
Acupuncture
Limited but positive evidence from small randomised trials on endometriosis-associated dysmenorrhoea. Best considered an adjunct, not a stand-alone treatment.
Diet and supplements
No solid data support a specific “anti-endometriosis” diet. A balanced, broadly anti-inflammatory dietary pattern (rich in fruits, vegetables, omega-3 fats, low in ultra-processed foods) can be part of a general wellness approach, but should not displace validated medical treatments. Dietary supplements (turmeric, omega-3, vitamin D, magnesium) have not shown meaningful clinical benefit and are not recommended in first line.
Special case: adolescents
Endometriosis can begin at menarche. Lesions are often atypical (red, vesicular) rather than pigmented. Disabling dysmenorrhoea, school absenteeism or pain refractory to standard analgesics warrants specific evaluation.
ESHRE 2022: “In adolescents with severe dysmenorrhoea and/or endometriosis-associated pain, clinicians should prescribe hormonal contraceptives or progestins (systemic or via the levonorgestrel-releasing IUS) as first-line treatment.”
Several principles guide management:
- Early hormonal treatment: continuous combined contraceptive or dienogest; LNG-IUS is a useful option in adolescents.
- Information on chronicity of the disease and the need for a long-term strategy.
- School and psychological support when pain is disabling.
- Surgery reserved for refractory cases, in specialised centres, with particular caution regarding future ovarian reserve.
- Fertility preservation: discussed case by case, especially if ovarian surgery is anticipated.
In practice
- First line: NSAIDs on demand + continuous combined hormonal contraceptives.
- Second line: dienogest 2 mg/day, or progestin alternative (LNG-IUS, implant).
- Third line: GnRH agonists with mandatory add-back, duration limited to 6–12 months, for refractory cases.
- Aromatase inhibitors: niche option, in specialised settings.
- Pelvic floor physiotherapy and CBT: integrate when myofascial or chronic-pain components warrant.
- Adolescents: early hormonal treatment as first line per ESHRE 2022.
- Always individualise: dose and duration are determined by your doctor, accounting for pregnancy plans, tolerance and co-morbidities.
FAQ
What is first-line treatment for pain?
NSAIDs on demand during painful periods, combined with a continuous combined hormonal contraceptive (pill, ring or patch, no monthly break) to suppress menstruation. That is the strong ESHRE 2022 recommendation.
Does dienogest cause weight gain?
Modest weight gain is possible but not systematic. Irregular bleeding is more frequent, especially early in treatment, before many patients transition to a well-tolerated amenorrhoea. Other common side effects include mood changes and sometimes lower libido.
Do GnRH agonists cause bone loss?
Yes, about 6 % per year without add-back, which is significant. That is why add-back with norethisterone or low-dose oestrogen plus progestin is now standard from day one, and treatment duration is limited to 6 to 12 months.
Can I become pregnant while on treatment?
Most suppressive hormonal treatments (CHC, dienogest, GnRH agonists) prevent pregnancy. If you have pregnancy plans, the treatment plan should be discussed and adjusted with your doctor. High-dose NSAIDs should be avoided when trying to conceive.
Does a specific diet help?
No specific diet has demonstrated solid clinical benefit. A balanced, broadly anti-inflammatory dietary pattern (fruits, vegetables, omega-3 fats, limited ultra-processed foods) can be part of a general approach without replacing validated medical treatments.
Is pelvic floor physiotherapy useful?
Yes, when a myofascial component is present — pelvic floor hypertonicity, musculoskeletal dyspareunia, residual pain after surgery. ESHRE 2022 recommends it as part of integrated care.
What if nothing works?
When successive medical steps and integrative care are insufficient, laparoscopic surgery may be discussed to treat lesions directly (excision rather than ablation), particularly in documented deep endometriosis. An expert centre is helpful in these situations.
My adolescent daughter has severe period pain — should we be concerned?
Disabling dysmenorrhoea in an adolescent, especially with school absenteeism or pain not responding to standard analgesics, should raise suspicion of early-onset endometriosis. First-line hormonal treatment (combined contraceptive or progestin) is recommended by ESHRE 2022 in this context.
Sources
- Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Human Reproduction Open 2022;2022(2):hoac009.
- Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis. Hum Reprod 2010;25(3):633–641.
- WHO. Endometriosis Fact Sheet, March 2023.
The content has been created by Dr. Senai Aksoy and medically approved.